|
🐢
|
Comparative effectiveness research and evidence-based health policy: experience from four countries.
7 auth.
K. Chalkidou,
S. Tunis,
R. Lopert,
L. Rochaix,
P. Sawicki,
M. Nasser,
...
B. Xerri
|
7 |
2009 |
7
🐢
|
|
🐜
|
Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger
12 auth.
G. Campagne,
A. Garba,
P. Fabre,
A. Schuchat,
R. Ryall,
D. Boulanger,
...
M. Bybel,
G. Carlone,
P. Briantais,
Bernard Anoff,
B. Xerri,
J. Chippaux
|
6 |
2000 |
6
🐜
|
|
🐬
|
Overview of health technology assessment in France
J. Orvain,
B. Xerri,
Y. Matillon
|
4 |
2004 |
4
🐬
|
|
🐬
|
Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine.
P. Bégué,
J. Stagnara,
F. Vié-le-Sage,
J. Bernard,
B. Xerri,
V. Abitbol
|
4 |
1997 |
4
🐬
|
|
🐜
|
Hepatitis A among health workers in Paris hospitals
9 auth.
M. Domart,
N. Mlika-Cabanne,
D. Henzel,
A. Pouliquen,
A. Florentin,
J. Marande,
...
B. Xerri,
A. Aufrère,
B. Larouzé
|
3 |
1999 |
3
🐜
|
|
🐢
|
National Authority for Health: France.
L. Rochaix,
B. Xerri
|
3 |
2009 |
3
🐢
|
|
🦁
|
Reactive polyarthritis induced by intravesical BCG therapy for carcinoma of the bladder.
B. Xerri,
Y. Chrétien,
J. Le Parc
|
3 |
1993 |
3
🦁
|
|
🐬
|
Relative effectiveness assessment of listed drugs (REAL): A new method for an early comparison of the effectiveness of approved health technologies
B. Falissard,
Valérie Izard,
B. Xerri,
G. Bouvenot,
F. Meyer,
L. Degos
|
3 |
2010 |
3
🐬
|
